Research Paper Volume 14, Issue 8 pp 3365—3386

Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties


Figure 6. Effects of inhibitors/natural products which may suppress metastasis on the growth of MIA-PaCa-2 + WT-TP53 and MIA-PaCa-2 + pLXSN cells. The effects of the tiplaxtinin Serpine-1 inhibitor (A), the natural product cyclopamine, a SHH inhibitor (B), the natural product parthenolide, a NF-κB inhibitor (C), and the natural product/nutraceutical isoliquiritin (D) were examined by MTT analysis. The MIA-PaCa-2 + WT-TP53, and MIA-PaCa-2 + pLXSN cells in each panel were all examined at the same time period. These experiments were repeated and similar results were obtained. Statistical analyses were performed by the T test on the means and standard deviations of various treatment groups. ***P < 0.0001.